Characterization of Anti-FGFR3 Antibodies

CompletedOBSERVATIONAL
Enrollment

251

Participants

Timeline

Start Date

February 3, 2015

Primary Completion Date

November 15, 2021

Study Completion Date

January 17, 2022

Conditions
Sensory Peripheral Neuropathy
Interventions
OTHER

Neurological assessment and Blood sample

Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening

Trial Locations (17)

13000

AP-HM, Marseille

38000

CHU de Grenoble, Grenoble

42055

Chu Saint-Etienne, Saint-Etienne

44093

CHRU de Nantes, Nantes

67000

Chu Strasbourg, Strasbourg

69000

Hospices Civils de Lyon, Lyon

75000

Hôpital BICETRE, Paris

75013

Hopital Pitie Salpetriere, Paris

75019

Fondation Rothschild, Paris

87000

CHU de Limoges, Limoges

94000

Chu Creteil, Créteil

Unknown

CHU Bordeaux, Bordeaux

CHU Clermont-Ferrand, Clermont-Ferrand

CHU Poitiers, Poitiers

CH Cornouailles, Quimper

CH Saint Denis - Hôpital Delafontaine, Saint-Denis

06000

CHU de NICE, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER

NCT02539329 - Characterization of Anti-FGFR3 Antibodies | Biotech Hunter | Biotech Hunter